

EXECUTIVE SUMMARY

First Quarter 2022




Main figures €Mn

REVENUE	EBITDA	EBIT
205.6 (+57%)	74.3 (+113%)	68.7 (+132%)
Net profit	Capex	Net cash
53.0 (+123%)	2.1 (-46%)	31.3

2022 operating revenue guidance: + 15 % - 20 %


ROVI receives the European Commission's approval of Okedi® as a treatment for schizophrenia and launches the product in Germany

Operating revenue €Mn



■ CMO business ■ Specialty pharmaceutical business

Specialty pharma business €Mn



Heparin franchise* €75.9 (+19%) 37% of operating revenue

LMWH €74.2 (+19%)

Bemiparin sales

€30.0m (-8%)

Spain

€17.5m (-8%)

International

€12.5m (-10%)

Enoxaparin sales

€44.2m (+50%)

✓ Directly marketed in Germany, UK, Italy, Portugal, Spain and Poland.

✓ Approved in 26 countries in Europe and 27 in RoW.

✓ Launched in 36 countries.


* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins

CMO business €Mn


Total
€95.0m

+167%


Gross profit €Mn



SG&A expenses €Mn



EBITDA €Mn




R&D expenses €Mn €4.8 -19%

Product	Potential Indication	Current Situation	Key Milestones
Okedi® Risperidone, monthly	Schizophrenia	Phase III	<ul style="list-style-type: none"> ✓ Approved in Europe ✓ In approval process in USA
Letrozole ISM® Long acting Letrozole	Breast Cancer	Phase I	Phase I started in November 2017
Risperidone, quarterly	Schizophrenia	Non-Clinical	

Concentrated on improving posology for already approved compounds, which benefits risk / reward profile

Multiple FDA / GMP approved facilities to support the platform

Net Profit €Mn



News flow

SPECIALTY PHARMA

- ✓ Sales of enoxaparin biosimilar
- ✓ Additional new products to be launched
- ✓ Granting by the competent local authorities of the marketing authorization of an Enoxaparin biosimilar outside Europe

CMO

- ✓ New contracts to be announced
- ✓ Evolution of Moderna's vaccine manufacturing.

ISM® Technology Platform

- ✓ Launch of Okedi® in Europe (already launched in Germany)
- ✓ Marketing authorization for Risvan® in USA
- ✓ Discussions with FDA initiated to review Letrozole ISM® phase I results as well as next steps